Study details
Enrolling now
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
Northwestern University
NCT IDNCT05042258ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
40
Study length
about 1.4 years
Ages
6–17
Locations
1 site in IL
About this study
Researchers are testing if dupilumab can improve sleep, reduce itching (pruritus), and help with circadian rhythm problems in children with moderate to severe atopic dermatitis. The trial will involve giving children dupilumab for 12 weeks and then having them undergo overnight sleep studies before and after treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Dupilumab
PhasePhase 4
DrugDupilumab
Primary goalPROMIS (Patient Reported Outcome Measurement Information System) parent-proxy score
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
dupilumab
Endpoints
Primary: PROMIS (Patient Reported Outcome Measurement Information System) parent-proxy score, PROMIS patient score
Body systems
Dermatology